Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Isabel Conceição et al.|New England Journal of Medicine|2018Cited by 1.4k
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialWilliam J. Litchy, John C. Kincaid, P. James B. Dyck et al.|Muscle & Nerve|2017Cited by 56
INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTRMathew S. Maurer, Merrill D. Benson, Stephen B. Heitner et al.|Journal of the American College of Cardiology|2018Cited by 6
Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)Thomas H. Brannagan, Morie A. Gertz, Annabel K. Wang et al.|Neurology|2018Cited by 2
Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001)Morie A. Gertz, Merrill D. Benson, Annabel K. Wang et al.|Neurology|2018Cited by 1